Glenmark Pharmaceuticals Ltd. - Research Center
532296 GLENMARK Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sales | 8,220.66 | 8,141.58 | 7,567.93 | 6,712.63 | 6,304.87 |
| Operating profit | 1,472.77 | 1,688.22 | 1,890.34 | 1,304.23 | 1,327.48 |
| Interest | 206.82 | 236.04 | 265.90 | 256.39 | 223.81 |
| Gross profit | 2,251.89 | 2,066.81 | 2,020.68 | 1,654.63 | 1,579.28 |
| EPS (Rs) | 42.84 | 70.80 | 58.46 | 48.00 | 57.49 |
Annual
results in details
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Other income | 985.94 | 614.63 | 396.24 | 606.79 | 475.61 |
| Stock adjustment | -31.37 | -16.13 | 5.24 | 48.77 | 471.81 |
| Raw material | 3,035.88 | 2,993.04 | 2,678.26 | 2,251.98 | 1,585.85 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,346.51 | 1,193.20 | 1,107.40 | 1,072.33 | 969.98 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 2,396.88 | 2,283.26 | 1,886.70 | 2,035.33 | 1,949.75 |
| Provisions made | - | - | - | - | - |
| Depreciation | 184.15 | 159.70 | 150.82 | 138.54 | 106.28 |
| Taxation | 363.11 | 339.66 | 294.31 | 180.10 | 329.88 |
| Net profit / loss | 1,208.77 | 1,997.79 | 1,649.45 | 1,354.55 | 1,622.11 |
| Extra ordinary item | -495.87 | 430.33 | 73.89 | 18.55 | 478.99 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 17.92 | 20.74 | 24.98 | 19.43 | 21.05 |
| GPM (%) | 24.46 | 23.60 | 25.37 | 22.61 | 23.29 |
| NPM (%) | 13.13 | 22.82 | 20.71 | 18.51 | 23.92 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis